Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

Massive FDA Staff Cuts Jeopardize Drug and Device Review Processes, Threatening Critical User Fee Programs

FDA layoffs , Drug review delays , User Fee Programs , PDUFA , Regulatory challenges , FDA budget cuts , Medical device approval , Biopharma regulatory issues , RFK Jr. HHS layoffs , FDA operational disruptions

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed

Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome

Advancing Aseptic Manufacturing: GRAM’s Vision for the Future of Sterile Drug Production

Aseptic manufacturing , Isolator technology, Automation and robotics, Flexible fill-finish capabilities, Advanced drug delivery systems, Regulatory compliance (Annex 1), Strategic partnerships, Patient-centric solutions